


**DEPARTMENT OF HEALTH AND HUMAN SERVICES
(includes BARDA and National Institutes of Health)**



Open solicitations:

www.sbir.gov/solicitations/open/hhs

Omnibus Solicitations:

PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

[PA-22-177](#)

Due dates **January 5, 2023; April 5, 2023**

PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

[PA-22-178](#)

Due dates **January 5, 2023; April 5, 2023**

PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

[PA-22-179](#)

Due dates **January 5, 2023; April 5, 2023**

PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

[PA-22-176](#)

Due dates **January 5, 2023; April 5, 2023**

**BARDA's Division of Research, Innovation & Ventures (DRIVE)
Easy Broad Agency Announcement (BAA)**

See the updated solicitation [BAA-20-100-SOL-0002](#) for more information, including program manager contact info. Read for updated deadlines for each area of interest.

Up to \$8 million available for 17 long-term areas of interest

BARDA continues to offer ongoing, long-term support for innovations in the health security, sepsis, and infectious disease spaces. Please refer to the current BARDA program for full details, including complete list of deadlines.

Original Date Offers Due: **February 03, 2023 05:00 pm EST**

NIH-specific solicitations

Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD)

(SBIR R43/R44 Clinical Trial Optional)

[PAS-22-196](#)

Due date **January 5, 2023; April 5, 2023**

Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD)

(STTR R41/R42 Clinical Trial Optional)

[PAS-22-197](#)

Due date **January 5, 2023; April 5, 2023**

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, Clinical Trial Not Allowed)

[PAR-20-128](#)

Due Date **January 5, 2023; April 5, 2023**

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)

[PAR-20-130](#)

Due Date **January 5, 2023; April 5, 2023**

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)

[PAR-20-129](#)

Due Date **January 5, 2023; April 5, 2023**

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
[RFA-DA-23-021](#)

Due Date **February 14, 2023**

Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44 Clinical Trial not Allowed)
[RFA-HG-21-008](#)

Due Date **February 1, 2023**

Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (STTR R41/R42 Clinical Trial Not Allowed)
[PAR-21-226](#)

Due Date **January 5, 2023; April 5, 2023**

Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (SBIR R43/R44 Clinical Trial Not Allowed)
[PAR-21-225](#)

Due Date **January 5, 2023; April 5, 2023**

NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
[RFA-HL-23-009](#)

Due Date **February 28, 2023**

NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
[RFA-HL-23-008](#)

Due Date **February 28, 2023**

NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (STTR R41/R42 Clinical Trial Optional)
[RFA-AG-23-030](#)

Due Date **February 17, 2023**

NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (SBIR R43/R44 Clinical Trial Optional)
[RFA-AG-23-029](#)

Due Date **February 17, 2023**

Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (SBIR U44 Clinical Trial Optional)
[PAR-21-057](#)

Due Date **February 22, 2023**

Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (SBIR U44 Clinical Trial Required)

[RFA-TR-22-029](#)

Due Date **March 15, 2023, July 12, 2023**

NINDS Exploratory Clinical Trials for Small Business (STTR R41/R42 Clinical Trial Required)

[PAR-21-267](#)

Due Date **January 5, 2023; April 5, 2023**

NINDS Exploratory Clinical Trials for Small Business (SBIR R43/R44 Clinical Trial Required)

[PAR-21-266](#)

Due Date **January 5, 2023; April 5, 2023**

NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (SBIR R44 Clinical Trial Optional)

[PAR-21-265](#)

Due Date **January 5, 2023; April 5, 2023**

NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (SBIR R44 Clinical Trial Not Allowed)

[PAR-21-114](#)

Due Date **January 5, 2023; April 5, 2023**

Translational Neural Devices (SBIR U44 Clinical Trial Optional)

[RFA-NS-21-022](#)

Due Date **February 21, 2023**

Blueprint Medtech: Small Business Translator (SBIR U44 - Clinical Trial Optional)

[PAR-21-282](#)

Due Date **February 21, 2023**

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (SBIR U44 Clinical Trial Optional)

[PAR -21-233](#)

Due Date **February 9, 2023**

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (SBIR U44 Clinical Trial Optional)

[PAR-20-111](#)

Due Date **February 9, 2023**

Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (SBIR U44 Clinical Trial Optional)

[PAR-21-059](#)

Due Date **February 22, 2023**

Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (SBIR U43/U44 Clinical Trial Optional)

[PAR-22-102](#)

Due Date **December 5, 2022**

Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (STTR UT1/UT2 Clinical Trial Optional)

[PAR-22-103](#)

Due Date **December 5, 2022**

NeuroNEXT Small Business Innovation in Clinical Trials (SBIR U44 Clinical Trial Optional)

[PAR-21-224](#)

Due Date **January 5, 2023**

NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (SBIR U44 Clinical Trial Required)

[PAR-21-082](#)

Due Date **January 13, 2023**

Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (STTR R41/R42 Clinical Trial Not Allowed)

[PAR-21-298](#)

Due Date **December 9, 2022**

Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (SBIR R43/R44 Clinical Trial Not Allowed)

[PAR-21-297](#)

Due Date **December 9, 2022**

Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed)

[PA-20-047](#)

Due Date **January 5, 2023**

Development of Highly Innovative Tools and Technology for Analysis of Single Cells (STTR) (R41/R42 Clinical Trial Not Allowed)

[PA-20-025](#)

Due Date **January 5, 2023**

HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)

[RFA-NS-23-007](#)

Due date: **January 4, 2023, April 4, 2023, September 4, 2023** (dates extend to April 4, 2025)

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)

[RFA-NA-23-006](#)

Due date: **January 4, 2023, April 4, 2023, September 4, 2023** (dates extend to April 4, 2025)

Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCH) (U43/U44 - Clinical Trial Not Allowed)

[RFA-TR-22-032](#)

Due Date: **February 22, 2023, August 21, 2023**

Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)

[PAR-23-032](#)

Earliest Submission Date: **December 5, 2022, April 5, 2023, September 5, 2023** (dates extend to September 5, 2025)

Innovation Corps (I-Corps™) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)

[PAR-22-073](#)

Next Due Date February 1, 2023